UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2146-14
Program Prior Authorization/Medical Necessity
Medication Aimovig® (erenumab), Ajovy® (fremanezumab)*, Emgality®
(galcanezumab)
P&T Approval Date 6/2018, 10/2018, 11/2018, 2/2019, 6/2019, 7/2019, 7/2020, 7/2021,
3/2022, 5/2022, 5/2023, 3/2024, 6/2024, 2/2025
Effective Date 5/1/2025
1. Background:
Aimovig, Ajovy*and Emgality 120 mg are calcitonin gene-related peptide receptor (CGRP)
antagonists indicated for the preventive treatment of migraine in adults. The 100 mg strength of
Emgality is indicated for the treatment of episodic cluster headache in adults.
2. Coverage Criteriaa:
A. Migraines
1. Initial Therapy
a. Aimovig or Emgality (120 mg strength) will be approved based upon all of the
following criteria:
1) Diagnosis of migraine consistent with The International Classification of
Headache Disorders, 3rd edition
-AND-
2) One of the following:
a) 4 to 7 migraine days per month and at least one of the following:
(1) Less than 15 headache days per month
-OR-
(2) Provider attests this is the member’s predominant headache diagnosis
(i.e., primary driver of headaches is not a different, non-migrainous
condition)
-OR-
b) Greater than or equal to 8 migraine days per month
-AND-
© 2025 UnitedHealthcare Services, Inc.
1
3) Failure (after a trial of at least two monthsb), contraindication or intolerance to
two of the following prophylactic therapies (document name and date tried)c:
a) One of the following beta-blockers: atenolol, metoprolol, nadolol,
propranolol, or timolol
b) Candesartan (Atacand)
c) Divalproex sodium (Depakote/Depakote ER)
d) OnabotulinumtoxinA (Botox) [Note: Coverage of onabotulinumtoxinA
(Botox) may be subject to additional benefit and coverage review
requirements]
e) a serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta),
venlafaxine (Effexor/Effexor XR)]
f) Topiramate (Topamax)
g) a tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]
-AND-
4) Medication will not be used in combination with another CGRP antagonist or
inhibitor used for the preventive treatment of migraines [e.g. Ajovy*, Nurtec®
ODT, Qulipta, Vyepti® (eptinezumab-jjmr)^]
b. Ajovy* will be approved based upon all of the following criteria:
1) Diagnosis of migraine consistent with The International Classification of
Headache Disorders, 3rd edition
-AND-
2) One of the following:
a) 4 to 7 migraine days per month and at least one of the following:
(1) Less than 15 headache days per month
-OR-
(2) Provider attests this is the member’s predominant headache diagnosis
(i.e., primary driver of headaches is not a different, non-migrainous
condition)
-OR-
b) Greater than or equal to 8 migraine days per month
-AND-
3) Failure (after a trial of at least two monthsb), contraindication or intolerance to
two of the following prophylactic therapies from the list below (document name
and date tried)c:
© 2025 UnitedHealthcare Services, Inc.
2
a) One of the following beta-blockers: atenolol, metoprolol, nadolol,
propranolol, or timolol
b) Candesartan (Atacand)
c) Divalproex sodium (Depakote/Depakote ER)
d) OnabotulinumtoxinA (Botox) [Note: Coverage of onabotulinumtoxinA
(Botox) may be subject to additional benefit and coverage review
requirements]
e) a serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta),
venlafaxine (Effexor/Effexor XR)]
f) Topiramate (Topamax)
g) a tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]
-AND-
4) Failure (after a trial of at least three monthsb), contraindication or intolerance to
two of the following (document date tried):
a) Aimovig
b) Emgality (120 mg strength)
c) Nurtec ODT
d) Qulipta
-AND-
5) Medication will not be used in combination with another CGRP antagonist or
inhibitor used for the preventive treatment of migraines (e.g., Aimovig, Emgality,
Nurtec ODT, Qulipta, Vyepti^)
Authorization will be issued for 12 months.
2. Reauthorization
a. Aimovig, Ajovy* or Emgality (120 mg strength) will be approved based on all of
the following criteria:
1) Patient has experienced a positive response to therapy, demonstrated by a
reduction in headache frequency and/or intensity
-AND-
2) Medication will not be used in combination with another CGRP antagonist or
inhibitor used for the preventive treatment of migraines (e.g., Nurtec ODT,
Qulipta, Vyepti^)
Authorization will be issued for 12 months.
B. Episodic Cluster Headache
1. Initial Therapy
© 2025 UnitedHealthcare Services, Inc.
3
a. Emgality (100 mg strength) will be approved based upon all of the following
criteria:
(1) Diagnosis of episodic cluster headache
-AND-
(2) Patient has experienced at least 2 cluster periods lasting from 7 days to 365 days,
separated by pain-free periods lasting at least three months.
-AND-
(3) Medication will not be used in combination with another CGRP antagonist or
inhibitor used for the preventive treatment of migraines (e.g., Aimovig, Ajovy*,
Nurtec ODT, Qulipta, Vyepti^)
Authorization will be issued for12 months.
2. Reauthorization
a. Emgality (100 mg strength) will be approved based on all of the following criteria:
(1) Patient has experienced a positive response to therapy, demonstrated by a
reduction in headache frequency and/or intensity
-AND-
(2) Medication will not be used in combination with another CGRP antagonist or
inhibitor used for the preventive treatment of migraines (e.g., Aimovig, Ajovy*,
Nurtec ODT, Qulipta, Vyepti^)
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
b For Connecticut, Kentucky and Mississippi business, only a 30-day trial will be required.
c For California business a trial of non-CGRP preventive treatments will not be required.
* Ajovy, is typically excluded from benefit coverage.
^Vyepti may be subject to additional benefit and coverage review requirements.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim
logic. Use of automated approval and re-approval processes varies by program and/or
therapeutic class.
• Notification, Step Therapy and Supply limits may be in place.
© 2025 UnitedHealthcare Services, Inc.
4
4. References:
1. Aimovig [package insert]. Thousand Oaks, CA: Amgen Inc; August 2024.
2. Ajovy [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc; October 2022.
3. Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; March 2021.
4. International Headache Society (IHS); Headache Classification Committee. The International
Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38:1-211.
5. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of
migraine: An American Headache Society position statement update. AHS Consensus Statement.
Headache. 2024; 64:333-41.
6. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum
neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache:
Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Neurology. 2016 May 10;86(19):1818-26.
Program Prior Authorization/Medical Necessity – CGRP antagonists
Change Control
6/2018 New program.
8/2018 Administrative update. Documented CT and KY duration of trial
regulation
10/2018 Added Ajovy and Emgality. Modified the trial and failure requirement
and removed the documentation requirement. Updated references.
11/2018 Removed the prescriber requirement.
2/2019 Modified the step therapy requirements for Ajovy.
6/2019 Removed - Medication will not be used in combination with
onabotulinumtoxinA (Botox) requirement.
7/2019 Added the episodic cluster headache indication and included approvable
strength for episodic and chronic migraine.
7/2020 Annual review. Updated initial authorization duration. Added
documentation requirement. Modified concomitant CGRP use to allow
non-biologic CGRPs.
7/2021 Annual review. Updated the criteria for episodic migraines. Combined
the criteria for episodic and chronic migraines. Added statement
regarding concomitant therapy with other preventive CGRPs. Updated
references.
3/2022 Added candesartan as a preventive option. Updated mandate language.
Added Qulipta as CGRP to not be used in combination with. Updated
the products typically excluded from coverage. Added note for Vyetpi
regarding additional benefit and coverage review requirements.
Updated references.
5/2022 Updated the migraine diagnostic criteria. Added Mississippi to state
mandate language.
5/2023 Annual review. Updated references.
© 2025 UnitedHealthcare Services, Inc.
5
3/2024 Annual review. Updated initial authorization to 12 months. Added
episodic to cluster headaches in section header. Updated mandate
language. Updated references.
6/2024 Removed notation that Qulipta is typically excluded from coverage.
Updated references.
2/2025 Added footnote for California specific requirement. Updated list of
potential prophylactic therapies. Added oral CGRP to the list of
required options for Ajovy. Updated references.
© 2025 UnitedHealthcare Services, Inc.
6